Study Summary
This trial will determine if using hemostatic agents during robotic partial nephrectomy affects complication rates.
- Kidney Cancer
Treatment Effectiveness
Phase-Based Effectiveness
Study Objectives
1 Primary · 4 Secondary · Reporting Duration: up to 6 months
Trial Safety
Phase-Based Safety
Awards & Highlights
Trial Design
2 Treatment Groups
Group 2 (Hemostatic Agents Negative -)
1 of 2
Group 1 (Hemostatic Agents Plus +)
1 of 2
Active Control
Experimental Treatment
178 Total Participants · 2 Treatment Groups
Primary Treatment: Hemostatic Agent · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 2 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
To what extent is enrollment progressing for this clinical research?
"Yes, the clinicaltrials.gov registry indicates that this is an ongoing trial with a start date of January 1st 2016 and most recently edited on June 3rd 2022. Currently, 178 individuals are being sought from one medical centre for participation in this study." - Anonymous Online Contributor
Is this medical experiment accepting new participants?
"The clinical trial is accepting applicants, as the data that can be found on clinicaltrials.gov attests to. The study was first put up in January 2016 and recently updated on June 3rd 2022." - Anonymous Online Contributor